Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




Celera and Medical Therapies (NASDAQ:CRA)

Jay Garcilazo (October 30th, 2009) Writes:

On a late Thursday evening, Celera Corporation (NASDAQ:CRA) and Medical Therapies Limited have announced that they have entered an exclusive license agreement for the use of Medical Therapies’ midkine patent portfolio for the development of novel lung cancer diagnostics. According to the license agreement, Celera will be able to use the Medical Therapies’ midkine patents for the commercialization and development of diagnostic products to address a range of lung cancer related applications which includes risk assessment, differentiation, prognosis, early detection system, disease progression, response to treatment and monitoring of reoccurrence. Celera Corporation and Medical Therapies Limited both are happy about the intellectual property agreement.

Celera Corporation is one of the upcoming healthcare companies that handles personalized disease management products and services and looks after three main segments which

...

Allion to be Acquired – Analyst Blog

Zacks Market Commentaries (October 19th, 2009) Writes:
Recently, Allion Healthcare Inc. (ALLI) inked a deal with an affiliate of H.I.G. Capital, LLC, a leading global private investment firm, whereby it agreed to be acquired by the private company. The deal is worth approximately $278 million. The amount is inclusive of the assumption or repayment of about $79 million of indebtedness. The transaction is expected to close in the first quarter of 2010.  Under the terms of the transaction, Allion shareholders would receive $6.60 per share in cash. This represents a premium of 30.2% over Allion's five-day average closing price before the announcement of the deal. Consequently, this transaction provides substantial financial gains to Allion shareholders. The transaction has been approved by Allion’s Board of Directors.  Additionally, other shareholders of Allion, including Parallex LLC, who in aggregate hold approximately 41.1 % of the company’s outstanding shares have agreed to vote in favor of the ...

Humana Creates New Health Benefit – Analyst Blog

Zacks Market Commentaries (October 12th, 2009) Writes:
Recently, Humana Military Healthcare Services, a wholly owned subsidiary of Humana Inc. (HUM), announced the availability of an additional benefit for the beneficiaries of the TRICARE program (a medical program under the Department of Defense) in the South Region.  Humana Military Healthcare Services offers health insurance coverage under the TRICARE program to the dependents of active duty military personnel and retired military personnel coupled with their dependents. Humana Military has been a contractor of the Department of Defense for the administration of the TRICARE program since Jul 1, 1996.  The new benefit provides the families of soldiers enrolled in the TRICARE program access to a Chronic Obstructive Pulmonary Disease (COPD) Management Program. They will be able to call a dedicated registered nurse and receive education and coaching on how to deal with this lung disease which blocks airflow thereby resulting in breathing difficulties.  Humana started ...

Zacks Bull and Bear of the Day Highlights: Allion Healthcare Inc., Embarq, EnCana, XTO Energy and Chesapeake – Press Releases

Zacks Market Commentaries (June 19th, 2009) Writes:
For Immediate Release

Chicago, IL - June 19, 2009 - Zacks Equity Research highlights Allion Healthcare Inc. (ALLI) as the Bull of the Day and Embarq (EQ) the Bear of the Day. In addition, Zacks Equity Research provides analysis on EnCana (ECA), XTO Energy (XTO) and Chesapeake (CHK).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676.

Here is a synopsis of all five stocks:

Bull of the Day:

Allion Healthcare Inc. (ALLI) is a national provider of specialty pharmacy and disease management services focused on HIV/AIDS patients. The company recently reported better-than-expected 1Q09 net income of $3.5M, or EPS of $0.13, compared with net income of $1.1M and EPS of $0.06 in 1Q08.

Organic growth in 1Q09 of the company's core Specialty HIV was 9% y/y, with the aggregate

...

Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.